Park Square is pleased to announce the placement of Doug Fambrough to the Board of Directors at Switch Therapeutics.
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.
unknownx500
More posts by Park Square Executive Search
Recent posts from Park Square Executive Search
